Supriya Shore1, Evan P Carey2, Mintu P Turakhia3, Cynthia A Jackevicius4, Fran Cunningham5, Louise Pilote6, Steven M Bradley1, Thomas M Maddox1, Gary K Grunwald7, Anna E Barón8, John S Rumsfeld1, Paul D Varosy1, Preston M Schneider1, Lucas N Marzec1, P Michael Ho9. 1. Veterans Affairs Eastern Colorado Health Care System, Denver, CO; University of Colorado-School of Medicine, Aurora, CO; Colorado Cardiovascular Outcomes Research Consortium, Denver, CO. 2. Veterans Affairs Eastern Colorado Health Care System, Denver, CO; Colorado Cardiovascular Outcomes Research Consortium, Denver, CO; University of Colorado-School of Public Health, Aurora, CO. 3. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Stanford University School of Medicine, Stanford, CA. 4. Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, CA; Western University of Health Sciences, Pomona, CA. 5. Veterans Affairs, Pharmacy Benefits Management Services and Center for Medication Safety, Hines, IL. 6. McGill University Health Center, Montréal, Québec, Canada. 7. Veterans Affairs Eastern Colorado Health Care System, Denver, CO; University of Colorado-School of Public Health, Aurora, CO. 8. University of Colorado-School of Public Health, Aurora, CO. 9. Veterans Affairs Eastern Colorado Health Care System, Denver, CO; University of Colorado-School of Medicine, Aurora, CO; Colorado Cardiovascular Outcomes Research Consortium, Denver, CO. Electronic address: michael.ho@va.gov.
Abstract
BACKGROUND: Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatran in the first year after initiation and assess the association between non-adherence to dabigatran and clinical outcomes in a large integrated healthcare system. METHODS: We studied a national cohort of 5,376 patients with NVAF, initiated on dabigatran between October-2010 and September-2012 at all Veterans Affairs hospitals. Adherence to dabigatran was calculated as proportion of days covered (PDC) and association between PDC and outcomes was assessed using standard regression techniques. RESULTS: Mean age of the study cohort was 71.3 ± 9.7 years; 98.3% were men and mean CHADS2 score was 2.4 ± 1.2 (mean CHA2DS2VASc score 3.2 ± 1.4). Median PDC was 94% (IQR 76%-100%; mean PDC 84% ± 22%) over a median follow-up of 244 days (IQR 140-351). A total of 1,494 (27.8%) patients had a PDC <80% and were classified as non-adherent. After multivariable adjustment, lower adherence was associated with increased risk for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in PDC). Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction. CONCLUSIONS: In the year after initiation, adherence to dabigatran for a majority of patients is very good. However, 28% of patients in our cohort had poor adherence. Furthermore, lower adherence to dabigatran was associated with increased adverse outcomes. Concerted efforts are needed to optimize adherence to NOACs. Published by Mosby, Inc.
BACKGROUND:Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatran in the first year after initiation and assess the association between non-adherence to dabigatran and clinical outcomes in a large integrated healthcare system. METHODS: We studied a national cohort of 5,376 patients with NVAF, initiated on dabigatran between October-2010 and September-2012 at all Veterans Affairs hospitals. Adherence to dabigatran was calculated as proportion of days covered (PDC) and association between PDC and outcomes was assessed using standard regression techniques. RESULTS: Mean age of the study cohort was 71.3 ± 9.7 years; 98.3% were men and mean CHADS2 score was 2.4 ± 1.2 (mean CHA2DS2VASc score 3.2 ± 1.4). Median PDC was 94% (IQR 76%-100%; mean PDC 84% ± 22%) over a median follow-up of 244 days (IQR 140-351). A total of 1,494 (27.8%) patients had a PDC <80% and were classified as non-adherent. After multivariable adjustment, lower adherence was associated with increased risk for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in PDC). Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction. CONCLUSIONS: In the year after initiation, adherence to dabigatran for a majority of patients is very good. However, 28% of patients in our cohort had poor adherence. Furthermore, lower adherence to dabigatran was associated with increased adverse outcomes. Concerted efforts are needed to optimize adherence to NOACs. Published by Mosby, Inc.
Authors: Michael P Gulseth; Ann K Wittkowsky; John Fanikos; Sarah A Spinler; William E Dager; Edith A Nutescu Journal: Pharmacotherapy Date: 2011-12 Impact factor: 4.705
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: William H Rogers; Lewis E Kazis; Donald R Miller; Katherine M Skinner; Jack A Clark; Avron Spiro; R Graeme Fincke Journal: J Ambul Care Manage Date: 2004 Jul-Sep
Authors: Robby Nieuwlaat; S Bertil Olsson; Gregory Y H Lip; A John Camm; Günter Breithardt; Alessandro Capucci; Joan G Meeder; Martin H Prins; Samuel Lévy; Harry J G M Crijns Journal: Am Heart J Date: 2007-06 Impact factor: 4.749
Authors: Kori Leblanc; William M Semchuk; John Papastergiou; Blair Snow; Leilany Mandlsohn; Vinay Kapoor; Lisa M Guirguis; James D Douketis; William Geerts; David J Gladstone Journal: Can Pharm J (Ott) Date: 2018-02-09
Authors: Marine Solano; Etienne Daguindau; Cyril Faure; Pierre Loriod; Coline Pain; Anne-Cécile Maes; Pauline Marguet; Marie Kroemer; Anne Rumpler; Jean Fontan; Eric Deconinck; Samuel Limat; Anne-Laure Clairet Journal: Ann Hematol Date: 2021-05-03 Impact factor: 3.673